SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5286-5292. Prepublished online as a Blood First Edition Paper on February 22, 2007; DOI 10.1182/blood-2007-01-065185. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-01-065185v1 109/12/5286    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Christiansen, V. J. Articles by McKee, P. A. Search for Related Content PubMed PubMed Citation Articles by Christiansen, V. J. Articles by McKee, P. A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The effect of a single nucleotide polymorphism on human 2-antiplasmin activity Victoria J. Christiansen1, Kenneth W. Jackson1, Kyung N. Lee1, and Patrick A. McKee1 1 William K. Warren Medical Research Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City    Abstract Top Abstract Introduction Materials and methods Results Discussion Authorship References   The primary inhibitor of plasmin, 2-antiplasmin (2AP), is secreted by the liver into plasma with Met as the amino-terminus. During circulation, Met-2AP is cleaved by antiplasmin-cleaving enzyme (APCE), yielding Asn-2AP, which is crosslinked into fibrin approximately 13 times faster than Met-2AP. The Met-2AP gene codes for either Arg or Trp as the sixth amino acid, with both polymorphic forms found in human plasma samples. We determined the Arg6Trp genotype frequency in a healthy population and its effects on Met-2AP cleavage and fibrinolysis. Genotype frequencies were RR 62.5%, RW 34.0%, and WW 3.5%. The polymorphism related to the percentage of Met-2AP in plasma was WW (56.4%), RW (40.6%), and RR (23.6%). WW plasma tended to have shorter lysis times than RR and RW plasmas. APCE cleaved purified Met-2AP(Arg6) approximately 8-fold faster than Met-2AP(Trp6), which is reflected in Asn-2AP/Met-2AP ratios with time in RR, RW, and WW plasmas. Removal of APCE from plasma abrogated cleavage of Met-2AP. We conclude that the Arg6Trp polymorphism is functionally significant, as it clearly affects conversion of Met-2AP to Asn-2AP, and thereby, the rate of 2AP incorporation into fibrin. Therefore, the Arg6Trp polymorphism may play a significant role in governing the long-term deposition/removal of intravascular fibrin.    Introduction Top Abstract Introduction Materials and methods Results Discussion Authorship References   The serine proteinase inhibitor, 2-antiplasmin (2AP), is a member of the serpin family, with plasmin as its primary target. Plasmin, generated from the zymogen plasminogen, plays a critical role in fibrin proteolysis and tissue remodeling.1 To prevent excessive proteolysis, regulation of plasminogen activators and plasmin inhibitors must occur. 2AP has been shown to be the most important inhibitor of plasmin, forming an irreversible inactive complex in what has been described as among the fastest proteinase-inhibitor reactions in biology.2–4 2AP is secreted into plasma as an approximately 70-kDa single polypeptide chain of 464 amino acids with Met as the amino-terminus.5 During circulation in plasma, 2AP undergoes proteolytic cleavage between Pro12-Asn13 to yield a slightly shortened version, with Asn as the amino-terminus.6 We have shown in vitro that the amino-terminally shortened Asn-2AP is crosslinked into fibrin approximately 13 times faster than its precursive form and that plasma clot lysis time is increased inversely to the Met-2AP/Asn-2AP ratio.7 The enzyme responsible for this cleavage was unknown until isolated and characterized in our laboratory, ultimately being termed antiplasmin cleaving enzyme (APCE) by us.7 We have since shown that APCE is essentially a soluble form of fibroblast activation protein (FAP), a type II integral membrane protein of the prolyl oligopeptidase family.8 When the Met-form of 2AP was found in plasma and its gene sequenced, there initially appeared to be a discrepancy in one of the nucleotides encoding the sixth amino acid. Two groups found a cytidine (C), resulting in Arg as the sixth amino acid, and one group found thymidine (T), resulting in Trp at that position.9–11 It was suggested that the difference was due to one group having used liver carcinoma cells as a source of DNA, while the other 2 groups used normal cells. It now has been determined that both Arg6 and Trp6 forms of Met-2AP exist in healthy human plasma samples. An investigation of a mutant 2AP in a family with bleeding tendencies identified the mutation responsible for the ineffective 2AP along with 3 polymorphisms in the 2AP gene, including this C/T single nucleotide polymorphism (SNP); this study examined 30 healthy blood donors and reported an allelic frequency of 0.81/0.19 for the C/T SNP.12 No larger studies of a healthy population have been done to examine the frequency of homozygotes and heterozygotes, or whether genotype might affect ratios of Met- to Asn-2AP in plasma. The Arg6Trp SNP apparently was assumed to be a silent polymorphism, but biochemical examination of the 2 polymorphic forms of Met-2AP on yielding the derivative form, Asn-2AP, its incorporation into fibrin and the impact on fibrinolysis have never been assessed. In this study, we first determined the prevalence of the polymorphism in a much larger healthy population and then assessed whether it relates to the inhibitory function of 2AP. We now report (1) genotype frequencies of the Arg6Trp SNP in Met-2AP; (2) how each form affects cleavage by APCE; (3) the percent of Met-2AP in plasma for each of the 2 polymorphisms; (4) plasma clot lysis times in relation to genotype; and (5) that removal of circulating APCE prevents conversion of Met- to Asn-2AP.    Materials and methods Top Abstract Introduction Materials and methods Results Discussion Authorship References   Materials Fresh frozen human plasma for the purification of proteins was purchased from the Sylvan Goldman Blood Institute (Oklahoma City, OK). Hybridoma cells secreting the F19 antibody were purchased from American Type Culture Collection (ATCC) (Manassas, VA) and grown in serum-free media; the F19 antibody was purified from culture media using MEP-Hypercel chromatography (Pall, East Hills, NY). Institutional review board (IRB) approval was obtained from University of Oklahoma Health Sciences Center for these studies (IRB #10142 and 12189). Isolation of 2AP Mixtures of Met-2AP and Asn-2AP were isolated by a modification7 of a published purification procedure using plasminogen kringles 1-3 attached to sepharose 4B as an affinity matrix.13 Met-2AP and Asn-2AP were separated by immunoaffinity chromatography as previously described.7 The ratio of Met-2AP to Asn-2AP in plasma samples was determined by comparison of picomole recovery of Met versus Asn in cycle one during automated protein sequencing by Edman degradation (Applied Biosystems Procise model 492, Foster City, CA). Isolation of APCE APCE was purified from human plasma as previously described.8 Briefly, a combination of ammonium sulfate precipitation, hydrophobic interaction, and immunoaffinity chromatography were used for purification. Before storing at –80°C, glycerol was added to the pure APCE to give a final concentration of 20%. Determination of 2AP genotype Two hundred randomly responding healthy volunteers, self-reported as healthy and free of acute illness, were recruited to donate blood for determination of genotype frequency and plasma clot lysis time (PCLT; see next section) in a normal population. DNA was isolated from whole blood of each donor using the AquaPure Genomic DNA Blood Kit (Bio-Rad, Hercules, CA). The portion of DNA encompassing the Arg6Trp SNP was amplified by polymerase chain reaction using oligonucleotide primers (5'-GACCTCCTATCCTCATCCCTTT and 5'-CTGGTTCGGCCCGCTAGTTAG), dNTPs (Takara Mirus Bio, Madison, WI), and Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA). Following amplification, the polymerase chain reaction (PCR) product was purified, using the MinElute PCR Purification Kit (Qiagen Operon, Alameda, CA) and sequenced, using an ABI3730 automated DNA sequencer. Measurement of plasma clot lysis To measure plasma clot lysis time, a mixture of 1 U/mL thrombin, 16 mM CaCl2, and 45 IU/mL urokinase (uPA) (Abbott, Chicago, IL) was added to each volunteer's plasma to catalyze essentially instant fibrin clot formation and to initiate fibrinolysis; the rate of plasma clot lysis was determined by a turbidimetric microtiter plate method.14–16 Determination of cleavage rates Reaction mixtures containing equal amounts (40 µg) of pure Met-2AP(Arg6) and pure Met-2AP(Trp6) were digested by APCE. At selected times the digestion was stopped by decreasing the pH from 7.5 to 4.0 with trifluoroacetic acid. Proteins were removed from the mixture by Microcon (Millipore, Bedford, MA) centrifugal ultrafiltration using a 30-kDa cutoff membrane. The peptides were isolated from the ultrafiltered digestion mixture by binding to POROS-50 reversed-phase media (Applied Biosystems, Foster City, CA) packed into a glass purification capillary (Proxeon, Odense, Denmark). The peptides were then eluted from the POROS-50 directly into a metal coated glass nanospray capillary with 2.0 µL of 0.5% acetic acid in 1:1 methanol/water. The nanospray capillary was mounted on the nanospray ionization source of a QSTAR ESI-Quad-TOF mass spectrometer operated under Analyst QS software version 1.0 (Applied Biosystems) with an ionspray voltage of 1400 volts. Data were collected over a mass range of 300 to 1500 Da. The relative quantities of the 2 2AP amino-terminal 12-amino acid peptides produced, MEPLGRQLTSGP, Mr = 1284.65 for Met-2AP(Arg6) and MEPLGWQLTSGP, Mr = 1314.63 for Met-2AP(Trp6), were determined by summing the areas of the 4 most abundant isotope peaks for the observed charge forms for each peptide. The data for each time point was normalized by a similar quantification of an added inert internal standard peptide that contained no proline. Determination of APCE antigen level An enzyme-linked immunosorbant assay (ELISA) was developed to determine antigen levels in human plasma. A goat antibody to the amino-terminal 15-amino acid sequence of APCE was prepared, using as the immunogen a multiple antigenic peptide (MAP) constructed in our laboratory to contain 8 copies of the amino-terminal peptide linked via their carboxyl-termini to a core peptide of 7 lysines.17 This goat MAP (amino-terminal 15 residue APCE peptide) antibody was bound to white high-binding polystyrene assay plates (Corning, Corning, NY) and used as the capture antibody. After incubation with dilutions of plasma, a monoclonal antibody purified from commercially available F19 hybridomas (ATCC) was applied, followed by peroxidase conjugated antimouse antibody (Sigma, St Louis, MO). A chemiluminescent substrate, SuperSignal ELISA Pico (Pierce, Rockford, IL), was added, and luminescence was monitored using a BIO-TEK FL600 plate reader (Winooski, VT). Antigen level was quantitated using purified human APCE as the standard. Removal of APCE from plasma The F19 mAb was linked to POROS EP 20 poly(styrenedivinylbenzene) perfusion chromatography beads (Applied Biosystems) and a nonspecific antibody, rabbit antigoat, was linked to the same type of media. Plasma from a single donor of the RR genotype was divided into 3 aliquots, diluted 1:1 with phosphate buffered saline (PBS) and incubated separately with each of the 2 bead-linked antibodies, nonspecific Ab or the F19 mAb, overnight at 4°C. The third aliquot received no treatment. The beads were removed from the plasma by filtration, and the plasma was then incubated at 29°C. Aliquots were removed at zero time, 24 hours, and 48 hours. 2AP was purified from each aliquot, and the Asn-2AP/Met-2AP ratio was determined as previously described. After removal from the plasma, the F19 mAb beads were washed with 25 mM Na PO4/0.5 M NaCl and then boiled with sodium dodecyl sulfate (SDS) loading buffer. The SDS buffer extract was then separated by electrophoresis on a 10% Bis-Tris gel (Invitrogen, Carlsbad, CA) and blotted to nitrocellulose. APCE was identified by Western blotting using the goat amino-terminal MAP antibody as described previously in this Methods section and visualized using SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate (Pierce).    Results Top Abstract Introduction Materials and methods Results Discussion Authorship References   2AP genotype determination A group of 201 healthy volunteers, who were recruited in 2 sets of approximately 100 people each, separated by about 2 years, provided blood samples for determining the 2AP C/T SNP frequency. The total population consisted of 61 men and 139 women 21 to 69 years of age, with an ethnicity that closely matched the demographics for an Oklahoma population as listed for the year 2000 on the US Census web site (factfinder.census.gov). Genotype was determined for 200 of the subjects. Only one DNA sample did not amplify by polymerase chain reaction, possibly due to a mutation that prevented binding of one of the primers, although this has not been further explored. The genotype frequencies for the 2 normal populations were essentially the same, with less than 1% difference for any of the genotypes. After combining the 2 sets, the frequencies for the entire population were RR 62.5%, RW 34.0%, and WW 3.5%. The R allele had a frequency of 79.5%, and the W allele had a frequency of 20.5%. There was no difference in the genotype frequency between men and women. Because the population was 72% Caucasian, with the other 28% split between 6 ethnic categories, it was not possible to determine whether genotype varied among ethnic groups. Met-2AP and Asn-2AP levels in plasma 2AP was purified from the plasmas of 15 persons of the RR genotype, 15 persons with RW, and 5 with WW genotype. The 2AP was sequenced by Edman degradation, and picomole recoveries of Met and Asn were determined for the first cycle to calculate the percent of Met-2AP and Asn-2AP. Figure 1 shows significantly different (P < .001) results that partitioned by genotype with WW having the highest percentage of Met-2AP (56.4%); RR, the least (23.6%); and RW falling in between (40.6%). View larger version (14K): [in this window] [in a new window]   Figure 1. Met-2AP as percent of total 2AP and by genotype. 2AP was purified from each plasma of persons with RR (n = 15), RW (n = 15), and WW (n = 5) genotypes and amino-terminal sequences determined by Edman degradation. Percent Met-2AP was calculated from picomole recoveries of Met and Asn in the first cycle.   To understand the mechanism for the varying percentages of Met-2AP in human plasma, we examined whether a variation in the level of enzyme that converts Met-2AP to Asn-2AP; that is, APCE, might explain the differences among the genotypes. To investigate this possibility, we developed an ELISA method for quantitating APCE antigen level in plasma and then determined APCE concentrations in plasma from 109 subjects in our normal population. As seen in Figure 2A, there is a distribution of APCE levels in normal human plasma, ranging from 38 to 159 ng/mL, that did not correlate with age or gender, and despite the suggestion of a possible association of APCE levels with genotype (RR, 70.4 ± 26; RW, 66.6 ± 24.5; WW, 64.7 ± 10.1), the differences were not statistically significant (Figure 2B). Therefore, APCE levels do not appear to account for the variation of Met-2AP levels among genotypes. View larger version (16K): [in this window] [in a new window]   Figure 2. Plasma APCE levels in a normal population and partitioned by genotype. APCE levels in plasma samples were determined by ELISA. (A) Histogram of APCE concentrations in a normal population (n = 109). (B) APCE levels by Met-2AP genotype.   Another explanation for the different Met-2AP percentages in the 3 genotypes might be that Met-2AP(Arg6) is a better substrate for APCE than Met-2AP(Trp6). To test this hypothesis, 2AP was purified from RR and WW plasma, and the cleavage rate of each polymorphic form, Met-2AP(Arg6) and Met-2AP(Trp6), was determined, using mass spectrometry to monitor the generation of the 12-residue amino-terminal peptide with time. As seen in Figure 3, comparisons of reaction rates were based on linear regression analysis of early time points and showed that APCE cleaves Met-2AP(Arg6) approximately 8-fold faster than Met-2AP(Trp6). View larger version (16K): [in this window] [in a new window]   Figure 3. APCE cleavage of polymorphic forms of Met-2AP. Equal amounts (40 µg) of purified Met-2AP(Arg6) and Met-2AP(Trp6) were digested by APCE. After stopping the reaction at selected times, samples were assessed by electrospray mass spectrometry for the quantity of the amino-terminal 12-amino acid peptide produced from each Met-2AP form.   To examine whether the cleavage rate of Met-2AP in whole plasma gave similar results based on the presence of R or W in position 6, fresh plasma samples from individuals whose genotype was determined to be RR, RW, and WW were obtained, incubated at 29°C, with each being analyzed at 0, 24, and 48 hours for Asn-2AP/Met-2AP ratios. 2AP was purified from each sample, and ratio of the 2 polymorphic forms was determined by picomole recovery of the amino-terminal residue in the first cycle of Edman degradation. As seen in Figure 4, Asn-2AP increased at a much greater rate in plasma from a healthy volunteer of the RR genotype than in either the RW or WW genotype patients. These results obviously concur with those from reaction mixtures of pure 2AP and APCE that showed APCE cleaves Met-2AP(Arg6) approximately 8-fold faster than Met-2AP(Trp6). View larger version (18K): [in this window] [in a new window]   Figure 4. Effect of Met-2AP genotype on generation of Asn-2AP in plasma with time. A plasma sample from a person of the RR, RW, or WW genotype was incubated at 29°C; at selected times 2AP was purified from each sample and subjected to amino-terminal sequence analysis. The ratio of Asn-2AP/Met-2AP was calculated from picomole recoveries of Met and Asn in the first cycle.   Plasma clot lysis Plasma clot lysis times (PCLTs) were determined on blood samples from the 200 women and men comprising the normal population. We did not attempt to control for variations of clot lysis that are known to occur due to activator release, activator-inhibitor interactions, fibrinogen level, or to effects of lipids on enzyme-substrate mechanisms; hence, gender, age, adrenergic status, smoking, obesity, alcohol consumption, serum lipid and fibrinogen measurements, medication, diurnal activities, etc, were disregarded as qualifiers for volunteer participation in the study. Instead, "all-comers" were entered so long as they reported themselves to be in good health, believing that study participants' lysis times should more or less reflect the "average" of all physiologic/pharmacologic effects within each genotype at any point in time and that if indeed the polymorphism detectably affected plasma clot lysis under our conditions, then its potential importance would be underscored. Important to emphasize is that mean PCLTs for men were significantly prolonged compared to values for women (P < .001). As depicted in Figure 5, mean PCLTs for the RR, RW, and WW genotype groups exhibited an impressive linear decrease, but the differences between mean PCLTs among the 3 genotypes were not statistically significant. As shown in panel A of Figure 5, after separating genotypes by gender, the differences for the mean PCLT among genotypes showed an obvious trend toward shorter lysis times for the WW genotype in both men and women. Since the distribution of PCLTs was skewed, nonparametric statistical methods were used to analyze the data. Medians for the RR and RW were similar and the distributions overlapped, suggesting that the R allele is dominant. When RR and RW groups were merged and compared to WW, after accounting for variation due to gender, the differences approached significance (P = .061). As noted in Figure 5B, 12 (10%) persons of the RR genotype and 2 (3%) of the RW genotype had plasma clots that remained totally intact during the entire one-hour assay period; no person of WW genotype had a lysis time more than 2100 seconds. View larger version (27K): [in this window] [in a new window]   Figure 5. Plasma clot lysis times (PCLT) by Met-2AP genotype. PCLTs were determined on plasma samples from RR, RW, and WW persons. (A) PCLT values were divided by genotype and plotted as mean ± SEM for the total population, men only and women only. (B) Percentage of plasmas that did not lyse (n = 14) compared to percentage of total population (n = 200) within each genotype.   Removal of APCE from plasma In an effort to definitively establish that APCE is the enzyme responsible for the conversion of Met-2AP to Asn-2AP, we removed APCE from plasma by incubating the plasma with the FAP-specific monoclonal antibody, F19, covalently attached to POROS chromatography beads. After removal of the beads, incubation of the plasma was continued for selected times at 29°C to allow conversion of Met-2AP to Asn-2AP. The graph in Figure 6 shows that the Asn-2AP/Met-2AP ratio in the control plasma, not incubated with the POROS-bound antibody, increased from 2.62 to 6.12 after 48 hours of incubation. In a second control, namely, plasma incubated with a nonspecific antibody bound to POROS chromatography beads, a significant increase in the Asn-2AP/Met-2AP ratio from 2.54 to 5.2 occurred after 48 hours. However, plasma incubated with the F19 antibody showed no increase in the Asn-2AP/Met-2AP ratio, 2.4 to 2.17, over the same incubation period, thereby indicating removal of APCE by the F19 antibody. These results clearly demonstrate that removal of APCE from plasma abrogates conversion of Met-2AP to the shorter, faster fibrin-crosslinking form, Asn-2AP. As further support for this conclusion, we also demonstrated by Western blot analysis that it was indeed APCE that was bound and removed by the bead-linked F19 mAb. Western blot analysis shown in Figure 6 shows an APCE monomeric 97-kDa band in the sample eluted from F19-linked beads; no such band was present on the rabbit antigoat (RAG) Ab-linked beads. Other bands visible were the result of nonspecific binding of the secondary Ab to immunoglobulin in the samples, which leaches off the beads during extraction by boiling in SDS. View larger version (22K): [in this window] [in a new window]   Figure 6. Effect of APCE removal on conversion of Met-2-AP to Asn-2-AP with time. Plasma was drawn from a person of RR Met-2AP genotype and divided into 3 aliquots. One aliquot was mixed with an APCE F19 mAb (F19) bound to chromatography beads and incubated at 4°C to remove APCE. The second aliquot was incubated at 4°C with a nonspecific rabbit -goat Ab (RAG) bound to beads. The third aliquot (RR) received no treatment. After removal of beads, each sample was incubated at 29°C, and Asn-2AP/Met-2AP ratios determined at selected times. In addition, F19-bound beads and RAG-bound beads were boiled with SDS to remove antibody-bound protein. Samples were electrophoresed on 10% Bis-Tris SDS-PAGE gels and blotted to nitrocellulose. APCE (97 kDa) was identified by Western blotting using a goat Ab to its amino-terminal region and visualized with a chemiluminescent substrate.      Discussion Top Abstract Introduction Materials and methods Results Discussion Authorship References   In the early nineteenth century, von Rokitansky and Virchow suggested that endothelial injury led to clotting activation and eventual platelet-fibrin accumulations at the site of damage.18,19 Since then, results of numerous studies support fibrin formation as integral in the developing atherogenic process.20–30 While the exact sequence of events that leads to plaque formation continues to be debated, there is more uniform agreement about fibrin deposition during the course of plaque growth, rupture, and acute thrombotic complications. Procoagulant processes that culminate in fibrin formation have been exhaustively studied, with elevations of selected clotting factor proteins or their activities considered as risk factors for atherogenesis or its acute complications.31–33 Similarly, diminished plasmin activity also has been implicated in plaque growth during the atherosclerotic process34–37 as well as in the persistence of occlusive thrombi when a plaque is disrupted.38,39 Rapid, effective plasmin inhibition over long periods of time would favor survival of intravascular platelet-fibrin deposits during the initiation of human atherogenesis and its progression. In contrast, enhanced plasmin activity would presumably digest and remove forming fibrin so that associated platelet deposits would become dispersed into the circulation. Genetic deficiencies of 2AP activity indicate that the homozygous state is associated with hemorrhage similar to that observed with factor XIII deficiencies; however, bleeding in heterozygotes appears to occur mainly after more serious injury or surgery, suggesting that enhanced fibrinolysis is clearly a feature of diminished 2AP function, but compatible with normal life.40 Conversely, functional 2AP levels have been purposefully raised to stabilize clot formation induced to occlude human patent ductus arteriosi,41 indicating that increased blood levels of 2AP make forming fibrin highly resistant to endogenous fibrinolysis. Finally, 2AP appears responsible for approximately 90% of plasmin inhibition in vivo,42–44 suggesting that functional levels of 2AP relate directly to thrombolytic rates. These observations indicate a significant regulatory role for 2AP in the thrombolytic process, perhaps even in the pathophysiology of atherosclerosis. The 2 populations of healthy volunteers we analyzed in separate time frames were essentially identical, with the pooled genotype frequency being RR, 62.5%; RW, 34.0%; and WW, 3.5%. The allelic frequency values of 0.795/0.205 are in accord with the only other study of which we are aware, namely that of Lind and Thorsen,12 who reported values of 0.81/0.19 for the single nucleotide transition in 30 healthy blood donors. Because this polymorphism occurs in the 12-residue amino-terminal peptide that is removed from the longer, precursive form of 2AP,6 and given that a positively charged hydrophilic arginine (R) is substituted with a hydrophobic amino acid, tryptophan (W), we questioned whether such a difference might affect the rate of cleavage of the peptide by APCE and subsequent incorporation into forming fibrin. We found that pure APCE cleaved pure Met-2AP of the WW genotype approximately 8 times slower when compared to pure Met-2AP from plasma of RR individuals. Figure 4 clearly shows that the native precursive Met-2AP/derivative Asn-2AP ratios in plasma samples containing each of the 2 polymorphic forms of Met-2AP change spontaneously with time when freshly drawn plasma is allowed to incubate at 29°C. This cleavage must be due to the naturally occurring plasma levels of APCE, since as shown in Figure 6, removal of APCE with a specific monoclonal antibody totally aborted generation of derivative Asn-2AP during the same incubation time. Since this cleavage occurs spontaneously within circulating blood,6 ratios of precursive Met-2AP/derivative Asn-2AP should vary within the circulating plasma from the 3 genotypes, which in fact we demonstrated by quantitative amino-terminal analysis of the precursive/derivative 2AP forms for each of the 35 persons analyzed. As predicted, persons of the RR genotype had the least amount of circulating Met-2AP (23.6%); with RW intermediate (40.6%), and WW the highest (56.4%). Our results cannot be explained by variation in APCE levels, since as depicted in Figure 2B, antigen levels were not significantly different among the 3 genotypes. The relationship between RR, RW, and WW genotypes and corresponding Met-2AP/Asn-2AP ratios raises the question of whether the latter might impact individuals' fibrinolytic activities so that over the course of one's life, vulnerability of intravascularly generated fibrin to endogenous fibrinolysis, and consequently its survival, are differentially affected by Met-2AP genotype. As a consequence, persons of the WW genotype would have Met-2AP that is less susceptible to cleavage by APCE and therefore less effectively incorporated into forming fibrin,7 thereby making any generated fibrin more susceptible to digestion by plasmin. We attempted to demonstrate this using whole plasma to approximate native conditions as closely as possible. As indicated in the prior section, only minimal effort was made to standardize conditions under which all samples were drawn from healthy volunteers, thinking that if indeed the WW genotype group had shortened fibrinolysis times, then odds should favor this being the case for the majority of time. Most of the perturbants known to affect fibrinolytic times—either acutely or chronically—are in play over one's lifetime, and in spite of such influences, we posited that on the average, fibrinolytic status would segregate according to Met-2AP genotype. Noteworthy is that in all our analyses, persons of RR genotype had the longest mean PCLT, with the RW group intermediate, and those in the WW genotype the shortest, suggesting that WW persons chronically have a more active fibrinolytic system than the RW group, and certainly greater activity than those with the RR genotype. The latter genotype contained a higher-than-expected percentage of persons whose fibrin never lysed, and if these were assigned PCLT values one second above the maximum measured value for any person in our study, then for men, the association of mean lysis times with RR and RW achieved significance at the P < .05 level. Our efforts were clearly compromised by the very significant difference in PCLTs we found for women compared to men, the relatively low prevalence of the WW polymorphism, and the characteristic mercurial responses of the human fibrinolytic system to a large array of physiologic and pharmacologic effectors. Despite these limitations, however, the apparent association of fibrin susceptibility to plasmin with the SNP described here prompts the interpretation that over one's lifetime, the W allele may serve as a "protection factor" (in contrast to the well-understood term, "risk factor") by increasing the susceptibility of developing intravascular thrombi to removal by plasmin. Evolutionarily the RR genotype may have posed an advantage for an individual's survival by maintaining structural integrity of blood clots so that life-threatening hemorrhage became fully staunched following wounding. While this would provide a breeding advantage during fertile years, over a full life span, the same genotype may become disadvantageous and indirectly participate in the pathogenesis of atherosclerotic disease by inhibiting fibrin digestion. Carefully designed genetic analyses of large-scale cardiovascular epidemiologic studies may determine if the prevalence of the WW genotype is significantly increased in those identified by multivariate cardiovascular risk analyses as having high risk for stroke, myocardial infarction, etc, but who otherwise remain free of events, or whether persons with late-onset, event-proven atherothrombotic cardiovascular disease have a disproportionate number of WW genotypes. Should the WW polymorphism be protective, the question of whether this can be addressed pharmacologically becomes apparent. It may be potentially useful to increase Met-2AP/Asn-2AP ratios to approximate those that accelerate fibrinolysis.7 If the function of 2AP—essentially the sole in vivo inhibitor of plasmin—could be decreased to levels that carry little risk of major bleeding, as exemplified in heterozygote deficiencies of 2AP function, and a chronic level of endogenous lytic activity sustained, then the survival and participation of intravascular fibrin-platelet thrombi in the atherosclerotic process should be reduced.    Authorship Top Abstract Introduction Materials and methods Results Discussion Authorship References   Contribution: V.J.C. designed research, performed research, collected data, analyzed data, and wrote the paper. K.W.J. designed research, performed research, analyzed data, and assisted in writing of the paper. K.N.L. designed research and assisted in writing of the paper. P.A.M. directed and designed research and wrote the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Victoria J. Christiansen, William K. Warren Medical Research Center, PO Box 26901, BSEB 306, Oklahoma City, OK 73190; e-mail: victoria-christiansen{at}ouhsc.edu.    Acknowledgments   This work was supported in part by the University of Oklahoma Health Sciences Center General Clinical Research Center grant M01-RR14467, sponsored by National Center for Research Resources-National Institutes of Health; and by William K. Warren Medical Research Center and National Institutes of Health grant HL072995 (V.J.C., K.W.J., K.N.L., and P.A.M.) We thank Ms D. Chissoe for excellent technical assistance.    Footnotes   Submitted January 1, 2007; accepted February 19, 2007. Prepublished online as Blood First Edition Paper, February 22, 2007 DOI: 10.1182/blood-2007-01-065185 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results Discussion Authorship References   Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82:259–270.[Medline] [Order article via Infotrieve] Wiman B and Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84:573–578.[Medline] [Order article via Infotrieve] Mullertz S and Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159:545–553.[Medline] [Order article via Infotrieve] Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69:209–216.[Medline] [Order article via Infotrieve] Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993; 291:623–625.[Medline] [Order article via Infotrieve] Koyama T, Koike Y, Toyota S, et al. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200:417–422.[CrossRef][Medline] [Order article via Infotrieve] Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103:3783–3788.[Abstract/Free Full Text] Lee KN, Jackson KW, Christiansen VJ, et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107:1397–1404.[Abstract/Free Full Text] Hirosawa S, Nakamura Y, Miura O, Sumi Y, Aoki N. Organization of the human alpha 2-plasmin inhibitor gene. Proc Natl Acad Sci U S A 1988; 85:6836–6840.[Abstract/Free Full Text] Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987; 262:1659–1664.[Abstract/Free Full Text] Tone M, Kikuno R, Kume-Iwaki A, Hashimoto-Gotoh T. Structure of human alpha 2-plasmin inhibitor deduced from the cDNA sequence. J Biochem 1987; 102:1033–1041.[Abstract/Free Full Text] Lind B and Thorsen S. A novel missense mutation in the human plasmin inhibitor (alpha2-antiplasmin) gene associated with a bleeding tendency. Br J Haematol 1999; 107:317–322.[CrossRef][Medline] [Order article via Infotrieve] Wiman B. Affinity-chromatographic purification of human alpha 2-antiplasmin. Biochem J 1980; 191:229–232.[Medline] [Order article via Infotrieve] Beebe DP and Aronson DL. An automated fibrinolytic assay performed in microtiter plates. Thromb Res 1987; 47:123–128.[CrossRef][Medline] [Order article via Infotrieve] Jones AJ and Meunier AM. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 64:455–463.[Medline] [Order article via Infotrieve] Lee KN, Lee SC, Jackson KW, et al. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis. Thromb Haemost 1998; 80:637–644.[Medline] [Order article via Infotrieve] Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A 1988; 85:5409–5413.[Abstract/Free Full Text] von Rokitansky C. Abnormal conditions of the arteries. A Manual of Pathological Anatomy. 1852;London, England Sydenham Society261–275. Virchow R. Phlogose und Thrombose im Gefasssystem. In Virchow R (Ed.). Gesammelte Abhandlungen zur Wissenschatflichen Medizin1856;Frankfurt, Germany Meidinger Sohn & Co pp. 458–636. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15:355–370.[Medline] [Order article via Infotrieve] Jorgensen L. The role of platelets in the initial stages of atherosclerosis. J Thromb Haemost 2006; 4:1443–1449.[CrossRef][Medline] [Order article via Infotrieve] Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH. Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost 1988; 14:189–195.[Medline] [Order article via Infotrieve] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242–250.[Medline] [Order article via Infotrieve] Bini A and Kudryk BJ. Fibrinogen in human atherosclerosis. Ann NY Acad Sci 1995; 748:461–471.[Medline] [Order article via Infotrieve] Bini A, Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis 1989; 9:109–121.[Abstract/Free Full Text] Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992; 86:III95–III99.[Medline] [Order article via Infotrieve] Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10:263–275.[Abstract/Free Full Text] Smith EB and Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73:1–19.[CrossRef][Medline] [Order article via Infotrieve] White JG. Platelets and atherosclerosis. Eur J Clin Invest 1994; 24:suppl 1, 25–29. Xiao Q, Danton MJ, Witte DP, et al. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998; 101:1184–1194.[Medline] [Order article via Infotrieve] Marutsuka K, Hatakeyama K, Yamashita A, Asada Y. Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb 2005; 12:1–8.[Medline] [Order article via Infotrieve] Kathiresan S, Yang Q, Larson MG, et al. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2006; 26:1405–1412.[Abstract/Free Full Text] Spurlock BO and Chandler AB. Adherent platelets and surface microthrombi of the human aorta and left coronary artery: a scanning electron microscopy feasibility study. Scanning Microsc 1987; 1:1359–1365.[Medline] [Order article via Infotrieve] Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076–1079.[CrossRef][Medline] [Order article via Infotrieve] Xiao Q, Danton MJ, Witte DP, et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A 1997; 94:10335–10340.[Abstract/Free Full Text] Kwaan HC. Physiologic and pharmacologic implications of fibrinolysis. Artery 1979; 5:285–290.[Medline] [Order article via Infotrieve] Smith EB. Haemostatic factors and atherogenesis. Atherosclerosis 1996; 124:137–143.[CrossRef][Medline] [Order article via Infotrieve] Juhan-Vague I and Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2:427–438.[Medline] [Order article via Infotrieve] Tanaka K and Sueishi K. The coagulation and fibrinolysis systems and atherosclerosis. Lab Invest 1993; 69:5–18.[Medline] [Order article via Infotrieve] Favier R, Aoki N, de MP. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol 2001; 114:4–10.[CrossRef][Medline] [Order article via Infotrieve] Eda K, Ohtsuka S, Seo Y, et al. Conservative treatment of hemolytic complication following coil embolization in two adult cases of patent ductus arteriosus. Jpn Circ J 2001; 65:834–836.[CrossRef][Medline] [Order article via Infotrieve] Levi M, Roem D, Kamp AM, et al. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69:141–146.[Medline] [Order article via Infotrieve] Harpel PC and Mosesson MW. Degradation of human fibrinogen by plasma alpha2-macroglobulin-enzyme complexes. J Clin Invest 1973; 52:2175–2184.[Medline] [Order article via Infotrieve] Aoki N and Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10:24–41.[Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. H. P. Law, T. Sofian, W.-T. Kan, A. J. Horvath, C. R. Hitchen, C. G. Langendorf, A. M. Buckle, J. C. Whisstock, and P. B. Coughlin X-ray crystal structure of the fibrinolysis inhibitor {alpha}2-antiplasmin Blood, February 15, 2008; 111(4): 2049 - 2052. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2007-01-065185v1 109/12/5286    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Christiansen, V. J. Articles by McKee, P. A. Search for Related Content PubMed PubMed Citation Articles by Christiansen, V. J. Articles by McKee, P. A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020